Which statement is true regarding compounding for drug shortages?

Compounding medications in response to drug shortages is governed by specific regulations to ensure that the practice is safe and compliant. The correct response encompasses the various requirements and regulatory frameworks involved.

For a compounded drug to be legally prepared in response to a shortage, it is indeed crucial that the drug is listed on the FDA's drug shortage list. This list identifies medications that are currently unavailable for commercial reasons and highlights the need for alternative preparations to ensure that patients have continued access to essential therapies.

Additionally, before compounding can occur, the state pharmacy board must grant an exemption from standard compounding regulations. This step is vital to maintain oversight and ensure that the compounding process meets safety and efficacy standards, particularly when responding to exigent circumstances like drug shortages.

Moreover, the Board has the authority to impose quantity restrictions on compounded medications. This control helps to prevent abuse and ensures that compounded products are adequately distributed among the patients who require them throughout the state, promoting fair access.

Collectively, these factors illustrate the careful balance between meeting patient needs and ensuring regulatory compliance during drug shortages. Therefore, all the statements pertaining to drug shortages are indeed accurate and reflect the comprehensive nature of the regulations governing compounding practices in such scenarios.